Pharmacy Times

JUNE 20, 2025

December 13, 2018. American Oncology Network. August 8, 2024. Accessed May 15, 2025. How your oncology peers manage the complexities of care. Oncology Live ®. Accessed May 15, 2025. Desimone R. Improve work performance with a focus on employee development. December 12, 2019. Updated January 19, 2024. Accessed May 15, 2025.

Pharmacy Technician

Pharmacy Times

JUNE 10, 2025

August 24, 2018. Additionally, like all NSAIDs, meloxicam injection should be used with caution in patients with cardiovascular, gastrointestinal, or renal risk factors. 2 REFERENCES 1. Schwenk E, Mariano E, et al. Designing the ideal perioperative pain management plan starts with multimodal analgesia. Korean Journal of Anesthesiology.

Pharmacy Technician

Pharmacy Times

JULY 24, 2025

Updated June 4, 2018. Accessed July 22, 2025. link] Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis. ClinicalTrials.gov identifier: NCT02893254. Accessed July 22, 2025.

Biosimilars

Pharmacy Times

JUNE 20, 2025

December 2018. link] articles/2018/12/dysmenorrhea-and-endometriosis-in-the-adolescent 4. American Pharmaceutical Association; 2025. Dysmenorrhea and endometriosis in the adolescent. American College of Obstetricians and Gynecologists. Accessed April 28, 2025. Smith RP, Kaunitz AM. UpToDate.

Pharmacy Technician

Pharmacy Times

JULY 8, 2025

These diseases are caused by a dysregulated mucosal immune response to the intestinal microflora in hosts who are genetically predisposed. The percentage of patients who initiated an infliximab biosimilar steadily increased from 1% in 2018 to almost 42% in 2023, with Inflectra outpacing the use of Renflexis and Avsola.

Biosimilars

pharmaphorum

JUNE 24, 2025

Skip to main content Tuesday 24 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Pharmacy Times

AUGUST 11, 2025

3 Since February 2018, ketamine has been regularly listed on the FDA’s drug shortage list, highlighting a significant need for a consistent and high-quality supply. Notably, the FDA did not express concern about the stability of the Ketarx submission batches, nor were new preclinical and clinical studies requested.

Pharmacy Technician

Pharmacy Times

JUNE 10, 2025

Thus, the reduced number of newly licensed pharmacists versus PharmD graduates: 2 In 2018, there were 14,905 PharmD graduates and 14,103 taking the NAPLEX for the first time. The number of PharmD graduates will likely dip below 10,000 in the next 5 years (a reduction of 33% from 2018).

Pharmacy Technician

Pharmacy Times

JULY 18, 2025

link] Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry, January 2018. Updated May 6, 2020. Accessed June 9, 2025. link] FDA Drug Shortages. Updated December 19, 2024. Accessed June 9, 2025.

Compounding

Pharmacy Times

JULY 1, 2025

031), and diagnosis between 2016 and 2018 (OR 1.93, P < 001) as well as 2019 and 2020 (1.88, P < 001). in 2016, representing a period of rapid uptake—and usage was consistently high from 2016 to 2018. 3 The utilization of HER2 therapies increased from 64.6% in 2013 to 80.9%

Pharmacy Technician

PharmaTech

JUNE 24, 2025

Some companies are combining mRNA vaccines with programmed cell death protein 1 (PD-1) inhibitors to activate the immune system and elicit tumour-specific T-cell responses. In 2018, following decades of research and development, the first RNA-based therapy, Onpattro (patisiran), from Alnylam Pharmaceuticals reached the market (10).

Vaccines

Putting Patients First Blog

JUNE 16, 2025

For example, incorporating immunization registries, social service data, and SDOH risk factors from trusted third-party sources would support holistic patient engagement tools. Developers would benefit from complementary integration with public sources such as the Area Deprivation Index and immunization registries. 9 (2018): 1259–1265.

Documentation

RX Note

JULY 5, 2025

Treatment directed at eradicating the inhibitor Immune tolerance induction (ITI) involves the regular infusion of factor VIII to induce antigen-specific tolerance. Although not commonly used in ITI protocols, immune modulation can improve tolerance success. Agents such as cyclophosphamide, intravenous immune globulin, rituximab.

HIV Treatment and Prevention Agents

RX Note

JULY 5, 2025

Treatment directed at eradicating the inhibitor Immune tolerance induction (ITI) involves the regular infusion of factor VIII to induce antigen-specific tolerance. Although not commonly used in ITI protocols, immune modulation can improve tolerance success. Agents such as cyclophosphamide, intravenous immune globulin, rituximab.

HIV Treatment and Prevention Agents

BioPharma Dive

JULY 16, 2025

Sarepta is working on a new regimen of immune-suppressing drugs to manage the safety risks, and plans to soon share its findings with the FDA. IPO activity has been depressed for years now, but the first half of the year brought only seven pricings, the lowest total BioPharma Dive has tracked since 2018 for the period.

Drug Pricing

Pharmacy Times

AUGUST 12, 2025

2018) backed these findings: hesperidin, piperine, and BV, when used together, strengthened the effects of tamoxifen on MCF-7 and T47D cells. 3 In the laboratory setting, work by Khamis et al. This was shown by apoptosis induction and G₂/M phase arrest in most treatment combinations.

Compounding

Pharmacy Times

AUGUST 7, 2025

Hoffmann-La Roche Ltd; Forma Therapeutics Holdings, Inc; Forty Seven, Inc; Genentech/Roche; Gilead Sciences; Hanmi Pharmaceutical; Immune-Onc Therapeutics, Inc; Incyte; Jazz Pharmaceuticals plc; Leadiant Biosciences; Lilly; Pfizer; Pharmacyclics Inc; and Treadwell Therapeutics. 2018;(38):555-573. Updated March 28, 2018.

Chemotherapy

The Thyroid Pharmacist

AUGUST 1, 2025

Benefits for the Baby Human breast milk is nutrient-rich and contains a variety of anti-inflammatory, immune-protective, and antimicrobial properties that support your baby’s immune system and reduce the risk of lower respiratory tract infections, ear infections (otitis media), and gastroenteritis. What does the research say?

Health and Personal Care Stores

pharmaphorum

AUGUST 13, 2025

Skip to main content Wednesday 13 August 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Diabetes

Express Pharma

JUNE 12, 2025

tumour cells continuously shed into the circulation, and while many are cleared by the immune system, some manage to evade immune defences and travel to distant sites in the body. Metastatic cancer refers to malignancies that originate in one organ and spread to adjacent or distant organs via the blood or lymphatic systems.

Chemotherapy

Beckers Hospital Review

AUGUST 8, 2025

Dr. Jarrett’s research experience has led to the publishing of his findings on the immune response in systemic lupus erythematosus, quality and cybersecurity in healthcare. Her contributions were instrumental in the successful merger of Barnabas Health and Robert Wood Johnson Health System, and she is a 2018 Baldrige Award recipient.

Hospitals

Pharmacy Times

JULY 7, 2025

Patients with dilated cardiomyopathy (DCM) or controls with normal cardiac MRI findings from January 2018 to December 2022 were included. is associated with diffuse myocardial fibrosis, a precursor to heart failure, as shown by increased native T1 z-scores in cardiac MRI. “We µm or smaller aerodynamic diameter (PM2.5)—which

Pharmacy Technician

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

pharmaphorum

JULY 17, 2025

Skip to main content Thursday 17 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Immunity

PharmaShots

JULY 23, 2025

All patients in the study had progressed following platinum-based chemotherapy, and 90% of patients had progressed after immune checkpoint inhibitors. Saurabh: Could you describe the study design of the Phase 1a/1b trial? As of the data cut-off date, we shared results from 89 patients across six dose cohorts (0.8 mg/kg, 1.2 mg/kg, 1.6

Chemotherapy

pharmaphorum

AUGUST 7, 2025

Skip to main content Thursday 7 August 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Diabetes

Pharmacy Times

JULY 23, 2025

" 2 Aluminum-containing adjuvants are frequently incorporated into non-live vaccines to strengthen the immune response by attaching to vaccine antigens. million children found no link between aluminum exposure from vaccines and chronic diseases.

Vaccines

pharmaphorum

JULY 18, 2025

Skip to main content Friday 18 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

STAT

JANUARY 3, 2023

More specifically, 70 of the 93 top-selling drugs covered by the Medicare Part B program – which are typically pricier medicines that are administered by physicians or in hospitals – between 2018 and 2020 would have been subject to inflationary rebates each year, according to the analysis published in JAMA.

Immunization

pharmaphorum

JULY 17, 2025

Skip to main content Thursday 17 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Immunity

BioPharma Dive

MAY 22, 2024

The deal, only Biogen’s third since the start of 2018, is a sign the company is open to branching out beyond the neurological drugs that have long been its focus.

Immunization

pharmaphorum

OCTOBER 26, 2022

has exited stealth with a $65 million Series A to create a new class of medicines that target novel I-O mechanisms, which free the body’s normal immunity against cancer. Called “immune normalisers”, these targets are drawn from an ongoing and interactive academic-biotech research alliance within the Yale School of Medicine.

Immunization

pharmaphorum

OCTOBER 17, 2022

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer. That’s what makes them such a tricky detective mystery!

Immunization

BioPharma Dive

MARCH 17, 2024

The biotech, formed as a successor to a company Roche acquired in 2018, has two drugs in clinical testing for neurological and immune diseases.

Immunization

pharmaphorum

JULY 13, 2022

In 2016 it started a $1 billion alliance with AstraZeneca to find drug candidates that could be used to treat respiratory diseases, and extended that in 2018 to include cardiovascular and metabolic disorders. Roche isn’t the only big pharma partner Bicycle has attracted for its bicyclic peptide technology.

Immunization

Pharmaceutical Technology

OCTOBER 14, 2022

They subsequently expanded the collaboration to include the development of antigen mRNA cancer vaccines in 2018. The mRNA-4157/V940 has been designed to stimulate an immune response by producing T-cell responses depending on the mutational signature of a patient's tumour.

Vaccines

pharmaphorum

JUNE 22, 2021

The US-based trial will enrol up to 280 participants aged 18 to 49 and will evaluate the safety of the mRNA vaccine candidate given at several dose levels, as well as its ability to stimulate an immune response against H3N2. billion, including $450 million of milestones from the original 2018 agreement.

Vaccines